These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 27636511)

  • 1. Growth factor pathways in hypertrophic scars: Molecular pathogenesis and therapeutic implications.
    Lian N; Li T
    Biomed Pharmacother; 2016 Dec; 84():42-50. PubMed ID: 27636511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological approaches for hypertrophic scars.
    Lingzhi Z; Meirong L; Xiaobing F
    Int Wound J; 2020 Apr; 17(2):405-418. PubMed ID: 31860941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keloids and Hypertrophic Scars: Pathophysiology, Classification, and Treatment.
    Berman B; Maderal A; Raphael B
    Dermatol Surg; 2017 Jan; 43 Suppl 1():S3-S18. PubMed ID: 27347634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation.
    Zhang T; Wang XF; Wang ZC; Lou D; Fang QQ; Hu YY; Zhao WY; Zhang LY; Wu LH; Tan WQ
    Biomed Pharmacother; 2020 Sep; 129():110287. PubMed ID: 32540643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of wound contraction. Basic and clinical features.
    Nedelec B; Ghahary A; Scott PG; Tredget EE
    Hand Clin; 2000 May; 16(2):289-302. PubMed ID: 10791174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management.
    Slemp AE; Kirschner RE
    Curr Opin Pediatr; 2006 Aug; 18(4):396-402. PubMed ID: 16914994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periostin induces fibroblast proliferation and myofibroblast persistence in hypertrophic scarring.
    Crawford J; Nygard K; Gan BS; O'Gorman DB
    Exp Dermatol; 2015 Feb; 24(2):120-6. PubMed ID: 25421393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids.
    Sato M
    Acta Derm Venereol; 2006; 86(4):300-7. PubMed ID: 16874413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of FKBP10 Attenuates Hypertrophic Scarring through Suppressing Fibroblast Activity and Extracellular Matrix Deposition.
    Liang X; Chai B; Duan R; Zhou Y; Huang X; Li Q
    J Invest Dermatol; 2017 Nov; 137(11):2326-2335. PubMed ID: 28774593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-Coding RNAs: The New Insight on Hypertrophic Scar.
    Chen L; Li J; Li Q; Yan H; Zhou B; Gao Y; Li J
    J Cell Biochem; 2017 Aug; 118(8):1965-1968. PubMed ID: 28067426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular basis of keloid and hypertrophic scar formation.
    Tuan TL; Nichter LS
    Mol Med Today; 1998 Jan; 4(1):19-24. PubMed ID: 9494966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathogenesis of hypertrophic/keloid scarring.
    Thomas DW; Hopkinson I; Harding KG; Shepherd JP
    Int J Oral Maxillofac Surg; 1994 Aug; 23(4):232-6. PubMed ID: 7798696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.
    Ogawa R; Akaishi S
    Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine mRNA changes during the treatment of hypertrophic scars with silicone and nonsilicone gel dressings.
    Ricketts CH; Martin L; Faria DT; Saed GM; Fivenson DP
    Dermatol Surg; 1996 Nov; 22(11):955-9. PubMed ID: 9063511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Keratinocytes on Myofibroblasts in Hypertrophic Scars.
    Lee JS; Kim JS; Lee JW; Choi KY; Yang JD; Cho BC; Oh EJ; Kim TJ; Ko UH; Shin JH; Jeon S; Lee YJ; Chung HY
    Aesthetic Plast Surg; 2019 Oct; 43(5):1371-1380. PubMed ID: 31346713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keloid and Hypertrophic Scars Are the Result of Chronic Inflammation in the Reticular Dermis.
    Ogawa R
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28287424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant Notch signalling contributes to hypertrophic scar formation by modulating the phenotype of keratinocytes.
    Li B; Gao C; Diao JS; Wang DL; Chu FF; Li Y; Wang G; Guo SZ; Xia W
    Exp Dermatol; 2016 Feb; 25(2):137-42. PubMed ID: 26566963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertrophic scars and keloids--a review of their pathophysiology, risk factors, and therapeutic management.
    Wolfram D; Tzankov A; Pülzl P; Piza-Katzer H
    Dermatol Surg; 2009 Feb; 35(2):171-81. PubMed ID: 19215252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keratinocyte-derived growth factors play a role in the formation of hypertrophic scars.
    Niessen FB; Andriessen MP; Schalkwijk J; Visser L; Timens W
    J Pathol; 2001 Jun; 194(2):207-16. PubMed ID: 11400150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-29b promotes skin wound healing and reduces excessive scar formation by inhibition of the TGF-β1/Smad/CTGF signaling pathway.
    Guo J; Lin Q; Shao Y; Rong L; Zhang D
    Can J Physiol Pharmacol; 2017 Apr; 95(4):437-442. PubMed ID: 28092445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.